# US 2017/0283397 A1 · Substituted 1-h-indol-3-yl-benzamide and 1, 1'-biphenyl analogs as histone demethylase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283397 A1
- Document ID: US20170283397A1
- Status: Published application
- Kind: A1
- Application number: 15/473,073
- Filed: 2017-03-29
- Published: 2017-10-05
- Earliest claimed: 2016-03-31
- Assignees: University of Utah Research Foundation
- Applicants: University of Utah Research Foundation
- Inventors: Hariprasad Vankayalapati; Sunil Sharma; Xiaohui Liu; Srinivas Kasibhatla
- Web page: https://patentgrep.com/patent/US20170283397A1

## CPC

- C07D 401/14: containing three or more hetero rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Substituted 1-H-indol-3-yl-benzamide and 1, 1′-biphenyl analogs derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including LSD1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the LSD1.

## Claims

### Claim 1

A compound having a structure of Formula I or II.
wherein:
n is selected from the group consisting of 0, 1 and 2;
X1 and X2 are independently selected from —CH and —N;
Z is selected from the group consisting of —O, —S, —NH, and —SO2;
R1 is selected from the group consisting of
R2 is selected from the group consisting of —H, —CH3, —HO, —NH2, halo, —CF3, OCF3, —OCH3, and CN, and wherein R2 can also be optionally substituted;
R3 is selected from the group consisting of C1-6 alkyl, C1-6 cycloalkyl, halo-C1-6 alkyl, cycloalkyl, and C1-6 heterocycloalkyl;
R4, R5 and R6 are each independently selected from the group consisting of —H, —CH3, —HO, —NH2, halo, —CF3, OCF3, —OCH3, and CN; and
R7 and R8 are each independently selected from the group consisting of —H and —CH3;
or an isomer or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein
n is 1;
X1 is —N;
X2 is —CH;
Z is selected from the group consisting of —O and —SO2;
R1 is selected from the group consisting of
R2 is —CH3;
R3 is selected from the group consisting of
R4 is —H;
R5 is halo;
R6 is —OH;
R7 and R8 are —H;
or an isomer or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein said compound is selected from the group consisting of:
or an isomer or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 5 (depends on 1)

A method for the treatment of a disorder of uncontrolled cellular proliferation in a mammal, the method comprising the step of administering to the mammal an effective amount of a compound of claim 1.

### Claim 6 (depends on 1)

A method for decreasing histone demethylase activity in a mammal, the method comprising the step of administering to the mammal an effective amount of a compound of claim 1.
